Profile of circulating microRNAs in myalgic encephalomyelitis and their relation to symptom severity, and disease pathophysiology.
Nepotchatykh, Evguenia, Elremaly, Wesam, Caraus, Iurie et al. · Scientific reports · 2020 · DOI
Quick Summary
This study looked at tiny molecules called microRNAs in the blood of severely ill ME/CFS patients before and after a stress challenge designed to trigger post-exertional malaise (the worsening of symptoms after activity). The researchers found that eleven different microRNAs changed in response to this challenge, with patterns that varied depending on symptom severity. These microRNA signatures could potentially be used one day as blood tests to help diagnose ME/CFS.
Why It Matters
ME/CFS currently lacks objective diagnostic biomarkers, making it difficult to confirm diagnosis and understand disease mechanisms. Identifying microRNA signatures that change during PEM provides potential biological markers that could improve diagnosis and may reveal clues about what goes wrong in ME/CFS at the molecular level. This could eventually lead to better detection methods and targeted treatments.
Observed Findings
Eleven circulating microRNAs showed differential expression in response to stress-induced PEM in severely ill ME/CFS patients.
MicroRNA expression patterns varied depending on the severity of specific symptoms.
The microRNA signatures were measurable in blood samples before and after the stress challenge protocol.
Distinct microRNA expression profiles emerged that were associated with ME/CFS versus baseline responses.
Inferred Conclusions
Specific microRNA expression signatures are characteristic of ME/CFS and change predictably during PEM induction.
MicroRNA patterns may serve as potential biomarkers for diagnosing ME/CFS and stratifying disease severity.
The physiological response to controlled PEM challenge can be detected at the molecular level through microRNA changes.
These findings suggest microRNA dysregulation is involved in ME/CFS pathophysiology.
Remaining Questions
Do these microRNA signatures remain stable over time or change with disease progression and treatment?
Can these microRNA patterns reliably distinguish ME/CFS from other similar conditions in diverse patient populations?
What This Study Does Not Prove
This study does not prove that these microRNA changes cause ME/CFS symptoms—only that they are associated with the disease and PEM response. The results come from severely ill patients in a laboratory setting, so the microRNA patterns may not represent all ME/CFS patients or explain the underlying mechanisms. The study also does not establish whether measuring these microRNAs alone would be reliable enough for clinical diagnosis without further validation.